1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Belarus Pharmaceuticals and Healthcare Report Q2 2016

Belarus Pharmaceuticals and Healthcare Report Q2 2016

  • February 2016
  • -
  • Business Monitor International
  • -
  • 75 pages

BMI View: Government initiatives to boost the nascent domestic pharmaceutical industry and reduce thereliance on imports will limit the attractiveness of Belarus to multinational drugmakers. Governmentinterference, in the form of domestic bias in the medicine tendering process and pricing controls, willfurther reduce revenue earning opportunities. Additional risks include a continued poor economic forecastand rising regional geopolitical tensions.Headline Expenditure ProjectionsPharmaceuticals: BYR12,247bn in 2015 (USD801mn) to BYR14,219bn (USD783mn) in 2016; +16.1% inlocal currency terms and -2.1% in US dollar terms.Healthcare: BYR60,885bn (USD3.98bn) in 2015 to BYR71,906bn (USD3.96bn) in 2016; +18.1% in localcurrency terms and -0.4% in US dollar terms.

Table Of Contents

Belarus Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Belarus 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belarus 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Belarus 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Belarus 2014-2020) 29
Industry Risk Reward Index 30
Central And Eastern Europe Risk/Reward Index 30
Belarus Risk/Reward Index 36
Rewards 36
Risks 37
Regulatory Review 39
Intellectual Property Issues 41
Pricing And Reimbursement Regime 42
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Belarus 2010-2015) 49
Table: Healthcare Personnel (Belarus 2010-2015) 49
Table: Healthcare Activity (Belarus 2010-2015) 50
Research And Development 50
Clinical Trials 51
Epidemiology 52
Competitive Landscape 56
Research-Based Industry 56
Table: Multinational Market Activity 57
Generic Drugmakers 58
Pharmaceutical Distribution 59
Pharmaceutical Retail Sector 60
Company Profile 61
Lekpharm 61
Demographic Forecast 64
Demographic Outlook 64
Table: Population Headline Indicators (Belarus 1990-2025) 65
Table: Key Population Ratios (Belarus 1990-2025) 65
Table: Urban/Rural Population and Life Expectancy (Belarus 1990-2025) 66
Table: Population By Age Group (Belarus 1990-2025) 66
Table: Population By Age Group % (Belarus 1990-2025) 67
Glossary 69
Methodology 71
Pharmaceutical Expenditure Forecast Model 71
Healthcare Expenditure Forecast Model 71
Notes On Methodology 72
Risk/Reward Index Methodology 73
Index Overview 74
Table: Pharmaceutical Risk/Reward Index Indicators 74
Indicator Weightings 75

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

  • $ 9 495
  • Industry report
  • May 2016
  • by Global Data

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024 Summary Huntington’s Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired ...

Asthma Pricing, Reimbursement, and Access

Asthma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the asthma market will be fueled by the introduction of new and expensive biologics, but companies will have to navigate access restrictions imposed by payers concerned about budget impact. This ...

Multiple Myeloma Pricing, Reimbursement, and Access

Multiple Myeloma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the multiple myeloma market will be spurred by the approval of novel drugs and the increasing role of combination therapy, but risk-sharing agreements will be key to entry into increasingly restrictive ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.